DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine ...

Lantern Pharma Inc. (NASDAQ:LTRN)’s investigational drug LP-184 has achieved a major milestone in the fight against pediatric brain cancer, following independent validation by Johns Hopkins University ...

Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drugcandidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. This ...

DALLAS - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotech company with a current market capitalization of approximately $31 million, has unveiled promising preclinical data for its drug ...

Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. This ...